Sun Enters Japan Through Divested Novartis Portfolio

Another multinational is shedding a portfolio of non-core mature products in Japan to a generics-focused company, as such drugs come under pricing pressure.

TOKYO - Sun Pharmaceutical Industries Ltd. is entering the Japanese pharma market by acquiring a bundle of 14 established prescription brands from Novartis AG‘s local subsidiary, in an anticipated move that echoes a similar transaction between Takeda Pharmaceutical Co. Ltd. and Teva Pharmaceutical Industries Ltd. last year.

A subsidiary of the Indian generics-focused firm will buy the therapeutically diverse portfolio - which has combined annual revenues of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from India

More from Focus On Asia